AstraZeneca selumetinib capsule approved in China

In vernacular On February 5, AstraZeneca's selumetinib capsule obtained the tacit clinical license for the treatment of symptomatic and / or progressive, inoperable neurofibromatosis type I (NF1) - related plexiform neurofibroma (PN) in children and adolescents over 3 years old Neurofibromatosis (NF) is a benign peripheral and central nervous system disease, which belongs to autosomal dominant genetic disease According to their clinical manifestations and gene loci, they are mainly divided into neurofibromatosis type 1 (NF1) and neurofibromatosis type 2 (NF2) It is estimated that the incidence rate of NF1 is about 1/3000~4000 newborn About 20-50% of NF1 patients may have plexiform neurofibroma, which is often not completely resected and has a high risk of recurrence NF1 patients may be accompanied by many complications, such as learning difficulties, visual impairment, spinal cord distortion and bending, hypertension and epilepsy NF1 also increases a person's risk of other cancers, including malignant brain tumors and leukaemia Selumetinib is a MEK 1 / 2 inhibitor MEK is a key protein kinase in Ras / MAPK signaling pathway The pathogenesis of NF1 is precisely because NF1 gene mutation disrupts the RAS / MAPK signaling pathway leading to tumor growth The drug was awarded orphan drug qualification by FDA in February 2018 In April 2019, it was awarded the title of breakthrough therapy by FDA Under a license agreement, AstraZeneca and MSD are jointly developing and commercializing selumetinib globally.